Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 127 entries
View as:

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06066125 Org: User:
Start: 03/31/23 End: 08/19/24 Due: 08/19/25

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05008783 Org: User:
Start: 09/17/21 End: 10/18/25 Due: 10/18/26

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Phase: N/A Priority: Normal
NCT ID: NCT05319431 Org: User:
Start: 06/28/22 End: 06/30/25 Due: 06/30/26

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT06756126 Org: User:
Start: 12/30/24 End: 06/30/25 Due: 06/30/26

A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05235516 Org: User:
Start: 06/21/22 End: 05/31/29 Due: 05/31/30

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT05096364 Org: User:
Start: 04/28/21 End: 02/03/23 Due: 02/03/24

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Phase: N/A Priority: Normal
NCT ID: NCT05260411 Org: User:
Start: 01/26/22 End: 12/19/22 Due: 12/19/23

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05393063 Org: User:
Start: 06/30/22 End: 06/30/24 Due: 06/30/25

A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04900363 Org: User:
Start: 05/21/21 End: 09/30/25 Due: 09/30/26

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04572152 Org: User:
Start: 12/07/20 End: 08/31/23 Due: 08/31/24

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05382442 Org: User:
Start: 06/27/22 End: 08/12/28 Due: 08/12/29

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05247684 Org: User:
Start: 02/20/22 End: 01/20/25 Due: 01/20/26

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05904379 Org: User:
Start: 07/13/23 End: 01/31/27 Due: 01/31/28

A Study of AK112 for Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04597541 Org: User:
Start: 10/21/20 End: 07/15/24 Due: 07/15/25

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04173637 Org: User:
Start: 12/19/19 End: 03/03/22 Due: 03/03/23

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05990127 Org: User:
Start: 11/14/23 End: 11/28/26 Due: 11/28/27

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06387420 Org: User:
Start: 04/29/24 End: 04/30/27 Due: 04/30/28

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05868876 Org: User:
Start: 06/29/23 End: 02/28/26 Due: 02/28/27

Study of AK119 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05173792 Org: User:
Start: 12/22/21 End: 05/22/23 Due: 05/22/24

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06928389 Org: User:
Start: 06/30/25 End: 06/30/30 Due: 06/30/31

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06642792 Org: User:
Start: 01/17/25 End: 02/29/28 Due: 02/28/29

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06560112 Org: User:
Start: 11/12/24 End: 05/01/27 Due: 05/01/28

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT05116007 Org: User:
Start: 03/29/21 End: 12/04/23 Due: 12/04/24

A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06953999 Org: User:
Start: 05/14/25 End: 05/14/28 Due: 05/14/29

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT07010263 Org: User:
Start: 05/29/25 End: 07/31/29 Due: 07/31/30